Literature DB >> 26351148

CD8⁺ T Cell-Independent Immune-Mediated Mechanisms of Anti-Tumor Activity.

G Elizabeth Pluhar1, Christopher A Pennell2, Michael R Olin3.   

Abstract

Despite the growing number of preclinical and clinical trials focused on immunotherapy for the treatment of malignant gliomas, the prognosis for this disease remains grim. Cancer immunotherapy seeks to recruit an effective immune response to eliminate tumor cells. To date, cancer vaccines have shown only limited effectiveness because of our incomplete understanding of the necessary effector cells and mechanisms that yield efficient tumor clearance. CD8+ T cell cytotoxic activity has long been proposed as the primary effector function necessary for tumor regression. However, there is increasing evidence that indicates that components of the immune system other than CD8+ T cells play important roles in tumor eradication and control. The following review should provide an understanding of the mechanisms involved in an effective antitumor response to guide future therapeutic designs. The information provided suggests an alternate means of effective tumor clearance in malignant glioma to the canonical CD8+ cytotoxic T cell mechanism.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26351148      PMCID: PMC4870933          DOI: 10.1615/critrevimmunol.2015013607

Source DB:  PubMed          Journal:  Crit Rev Immunol        ISSN: 1040-8401            Impact factor:   2.214


  166 in total

1.  Cutting edge: MHC class II-restricted killing in vivo during viral infection.

Authors:  Evan R Jellison; Sung-Kwon Kim; Raymond M Welsh
Journal:  J Immunol       Date:  2005-01-15       Impact factor: 5.422

2.  Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Valpha14 NKT cells.

Authors:  T Kawano; J Cui; Y Koezuka; I Toura; Y Kaneko; H Sato; E Kondo; M Harada; H Koseki; T Nakayama; Y Tanaka; M Taniguchi
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-12       Impact factor: 11.205

Review 3.  The role of peptide presentation in the physiological function of HLA-G.

Authors:  C Münz; P Nickolaus; E Lammert; S Pascolo; S Stevanović; H G Rammensee
Journal:  Semin Cancer Biol       Date:  1999-02       Impact factor: 15.707

4.  A novel function of Valpha14+CD4+NKT cells: stimulation of IL-12 production by antigen-presenting cells in the innate immune system.

Authors:  M Tomura; W G Yu; H J Ahn; M Yamashita; Y F Yang; S Ono; T Hamaoka; T Kawano; M Taniguchi; Y Koezuka; H Fujiwara
Journal:  J Immunol       Date:  1999-07-01       Impact factor: 5.422

Review 5.  The immunoregulatory role of type I and type II NKT cells in cancer and other diseases.

Authors:  Masaki Terabe; Jay A Berzofsky
Journal:  Cancer Immunol Immunother       Date:  2014-01-03       Impact factor: 6.968

6.  Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo.

Authors:  Mei-Ling Chen; Mikaël J Pittet; Leonid Gorelik; Richard A Flavell; Ralph Weissleder; Harald von Boehmer; Khashayarsha Khazaie
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-27       Impact factor: 11.205

7.  Emergence of a CD4+CD28- granzyme B+, cytomegalovirus-specific T cell subset after recovery of primary cytomegalovirus infection.

Authors:  Ester M M van Leeuwen; Ester B M Remmerswaal; Mireille T M Vossen; Ajda T Rowshani; Pauline M E Wertheim-van Dillen; René A W van Lier; Ineke J M ten Berge
Journal:  J Immunol       Date:  2004-08-01       Impact factor: 5.422

Review 8.  Regulation of antitumour immunity by CD1d-restricted NKT cells.

Authors:  Jeremy Swann; Nadine Y Crowe; Yoshihiro Hayakawa; Dale I Godfrey; Mark J Smyth
Journal:  Immunol Cell Biol       Date:  2004-06       Impact factor: 5.126

9.  Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay.

Authors:  M J Bevan
Journal:  J Exp Med       Date:  1976-05-01       Impact factor: 14.307

10.  Immunosuppression induced by immature dendritic cells is mediated by TGF-beta/IL-10 double-positive CD4+ regulatory T cells.

Authors:  N Cools; V F I Van Tendeloo; E L J M Smits; M Lenjou; G Nijs; D R Van Bockstaele; Z N Berneman; P Ponsaerts
Journal:  J Cell Mol Med       Date:  2008-04       Impact factor: 5.310

View more
  10 in total

1.  Chemokine CXCL3 mediates prostate cancer cells proliferation, migration and gene expression changes in an autocrine/paracrine fashion.

Authors:  Hua Xin; Yu Cao; Ming-Liang Shao; Wei Zhang; Chun-Bin Zhang; Jing-Tao Wang; Li-Chun Liang; Wen-Wu Shao; Ya-Ling Qi; Yue Li; Ze-Yu Zhang; Zhe Yang; Yu-Hong Sun; Peng-Xia Zhang; Lin-Lin Jia; Wei-Qun Wang
Journal:  Int Urol Nephrol       Date:  2018-03-09       Impact factor: 2.370

2.  Co-culture Systems of Drug-Treated Acute Myeloid Leukemia Cells and T Cells for In Vitro and In Vivo Study.

Authors:  Yangchan Li; Rui Su; Jianjun Chen
Journal:  STAR Protoc       Date:  2020-08-28

3.  Enhanced Immunotherapy with LHRH-R Targeted Lytic Peptide in Ovarian Cancer.

Authors:  Mark Seungwook Kim; Shaolin Ma; Anca Chelariu-Raicu; Carola Leuschner; Hector W Alila; Sanghoon Lee; Robert L Coleman; Anil K Sood
Journal:  Mol Cancer Ther       Date:  2020-09-17       Impact factor: 6.009

4.  Expression of a novel CNPY2 isoform in colorectal cancer and its association with oncologic prognosis.

Authors:  Jianhong Peng; Qingjian Ou; Jian Guo; Zhizhong Pan; Rongxin Zhang; Xiaojun Wu; Yujie Zhao; Yuxiang Deng; Caixia Li; Fulong Wang; Liren Li; Gong Chen; Zhenhai Lu; Peirong Ding; Desen Wan; Yujing Fang
Journal:  Aging (Albany NY)       Date:  2017-11-13       Impact factor: 5.682

Review 5.  Consequences of EMT-Driven Changes in the Immune Microenvironment of Breast Cancer and Therapeutic Response of Cancer Cells.

Authors:  Snahlata Singh; Rumela Chakrabarti
Journal:  J Clin Med       Date:  2019-05-09       Impact factor: 4.241

Review 6.  Cytokine and Chemokine Signals of T-Cell Exclusion in Tumors.

Authors:  Yu Zhang; Xin-Yuan Guan; Peng Jiang
Journal:  Front Immunol       Date:  2020-12-14       Impact factor: 7.561

7.  Pharmacological inhibition of hematopoietic progenitor kinase 1 positively regulates T-cell function.

Authors:  Yun Wang; Kelvin Zhang; Peter Georgiev; Steven Wells; Haiyan Xu; Brian M Lacey; Zangwei Xu; Jason Laskey; Robbie Mcleod; Joey L Methot; Mark Bittinger; Alexander Pasternak; Sheila Ranganath
Journal:  PLoS One       Date:  2020-12-03       Impact factor: 3.240

8.  Immunoexpression of PD-L1, CD4+ and CD8+ cell infiltrates and tumor-infiltrating lymphocytes (TILs) in the microenvironment of actinic cheilitis and lower lip squamous cell carcinoma.

Authors:  Vinícius Gonçalves de Souza; Damilys Joelly Souza Santos; Ana Gabriela Silva; Rosy Iara Maciel de Azambuja Ribeiro; Adriano Mota Loyola; Sérgio Vitorino Cardoso; Carla Silva Siqueira Miranda; Ludimila Paula Vaz Cardoso
Journal:  J Appl Oral Sci       Date:  2022-02-21       Impact factor: 2.698

Review 9.  The potential of gas plasma technology for targeting breast cancer.

Authors:  Sander Bekeschus; Fariba Saadati; Steffen Emmert
Journal:  Clin Transl Med       Date:  2022-08

10.  Pro-Resolving Factor Administration Limits Cancer Progression by Enhancing Immune Response Against Cancer Cells.

Authors:  Audrey Wetzel; Francis Bonnefoy; Cécile Chagué; Mathieu Vetter; Mélanie Couturier; Blandine Baffert; Olivier Adotévi; Philippe Saas; Sylvain Perruche
Journal:  Front Immunol       Date:  2022-01-18       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.